Abstract: A pharmaceutical composition containing a compound of Formula 1 or Formula 2 below or a pharmaceutically acceptable salt thereof. The composition is suitable for preventing or treating RON-mutation-associated biliary tract cancer. The pharmaceutical composition can be applied to a biliary tract cancer patient having a RON mutation. Particularly, the pharmaceutical composition can be effectively used for treating a biliary tract cancer patient who is resistant to cetuximab, which is conventionally used for cancer treatment, and who has mutation at RONA 155, RON?160 or RON?165.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating small cell lung cancer associated with a RON mutation and a method using the same. The compound according to the present invention may be usefully used as a precision medicine in the treatment of a patient with small cell lung cancer which has resistance to an EGFR-targeted therapeutic agent used in conventional anticancer therapy and has the RON?155, RON?160, and RON?165 mutations.